Dabigatran Etexilate: Cost-Effective Analysis
STUDY PAPER 2:
Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrilation in Different Age Subgroups
Title and abstract
Item 1: Title
The purpose of this study is to perform cost-effectiveness analysis (CEA) to determine the cost effectiveness of Diabigatran Etexilate. In this study, the researcher studied about Dabigatran Etexilate as an intervention and compared its effectiveness for stroke and systemic embolism risk reduction with Warfarin which is a comparator in patients of different age group with atrial fibrillation.
Item 2: Abstract
Background:
Objective :This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk …show more content…
Results of base-case analysis: The RE-LY analysis shows that the 75 cohort; versus warfarin, dabigatran performed better in main efficacy and safety in all age cohorts with the exception of extracranial hemorrhage in the >75 cohort.
Results of sensitivity analysis: undefined in abstract
Limitations: not mentioned in abstract
Conclusions : Dabigatran was cost-effective versus warfarin in US patients with atrial fibrillation regardless of age of treatment initiation.
Primary Funding Source: not mentioned in abstract but defined in funding section.
Limitation: the study did not clearly mention the limitation in the abstract.
Introduction
Item 3: Introduction
In this article, the author define the keyword atrial fibrillation stating that it is a common arrhythmia and is leading cause of stroke. The researcher clarified the purpose of conducting Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial which is to demonstrate the safety and efficacy of dabigatran versus warfarin for the prevention of stroke and systemic embolism, and in additional analyses, the efficacy and safety by age cohorts in patients with AF at moderate to high risk of stroke. It is stated that the effects of dabigatran versus warfarin on stroke or systemic embolism were consistent across age cohorts, but a there is a significant interaction between treatment …show more content…
The advantages of dabigatran etexilate over warfarin including no need for regular blood test, no dietary restriction and no dosage adjustment required.[17] There is a lack of healthcare professionals in our hospitals, hence frequent therapeutic drug monitoring of warfarin is burdensome.If dabigatran is introduced in our hospital setting, we can help to reduce some workload of healthcare provider in our hospital, and this will also benefits patients with atrial
Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrilation in Different Age Subgroups
Title and abstract
Item 1: Title
The purpose of this study is to perform cost-effectiveness analysis (CEA) to determine the cost effectiveness of Diabigatran Etexilate. In this study, the researcher studied about Dabigatran Etexilate as an intervention and compared its effectiveness for stroke and systemic embolism risk reduction with Warfarin which is a comparator in patients of different age group with atrial fibrillation.
Item 2: Abstract
Background:
Objective :This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk …show more content…
Results of base-case analysis: The RE-LY analysis shows that the 75 cohort; versus warfarin, dabigatran performed better in main efficacy and safety in all age cohorts with the exception of extracranial hemorrhage in the >75 cohort.
Results of sensitivity analysis: undefined in abstract
Limitations: not mentioned in abstract
Conclusions : Dabigatran was cost-effective versus warfarin in US patients with atrial fibrillation regardless of age of treatment initiation.
Primary Funding Source: not mentioned in abstract but defined in funding section.
Limitation: the study did not clearly mention the limitation in the abstract.
Introduction
Item 3: Introduction
In this article, the author define the keyword atrial fibrillation stating that it is a common arrhythmia and is leading cause of stroke. The researcher clarified the purpose of conducting Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial which is to demonstrate the safety and efficacy of dabigatran versus warfarin for the prevention of stroke and systemic embolism, and in additional analyses, the efficacy and safety by age cohorts in patients with AF at moderate to high risk of stroke. It is stated that the effects of dabigatran versus warfarin on stroke or systemic embolism were consistent across age cohorts, but a there is a significant interaction between treatment …show more content…
The advantages of dabigatran etexilate over warfarin including no need for regular blood test, no dietary restriction and no dosage adjustment required.[17] There is a lack of healthcare professionals in our hospitals, hence frequent therapeutic drug monitoring of warfarin is burdensome.If dabigatran is introduced in our hospital setting, we can help to reduce some workload of healthcare provider in our hospital, and this will also benefits patients with atrial